表紙
市場調査レポート

スペシャルティCRO市場:2016-2025年

Specialty CROs Market, 2016 - 2025

発行 ROOTS ANALYSIS 商品コード 352701
出版日 ページ情報 英文 321 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
スペシャルティCRO市場:2016-2025年 Specialty CROs Market, 2016 - 2025
出版日: 2016年02月12日 ページ情報: 英文 321 Pages
概要

当レポートでは、特定の臨床開発段階または治療領域へサービス範囲の重点を置いて専門的な研究機能を提供するスペシャルティCRO (医薬品開発業務受託機関) について包括的に調査し、スペシャルティCROの発展に影響を及ぼす主な促進因子の評価と近い将来の市場を形成すると見込まれる動向についての議論を提供しており、地理的なロケーション、提供サービスのタイプ、および重点を置く治療領域など主要パラメーターに基づいた詳細分析をまとめ、お届けいたします。

第1章 序章

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 歴史
  • 従来の医薬品開発業務受託機関 (CRO)
    • サービス
    • 現在の産業環境
  • スペシャルティCRO

第4章 スペシャルティCRO:イントロダクション

  • 本章の概要
  • スペシャルティCROの重要性

第5章 市場概要

  • 本章の概要
  • 調査手法
  • スペシャルティCRO:世界の情勢
  • 特定のサービス能力にフォーカスしたスペシャルティCRO
  • 特定の治療領域にフォーカスしたスペシャルティCRO

第6章 スペシャルティCRO:サービスへのフォーカス

  • 本章の概要
  • 前臨床サービス能力にフォーカスしたCRO
  • 臨床サービス能力にフォーカスしたCRO

第7章 スペシャルティCRO:治療領域へのフォーカス

  • 本章の概要
  • 癌にフォーカスしたスペシャルティCRO
  • 心血管/心臓学にフォーカスしたスペシャルティCRO
  • 代謝疾患にフォーカスしたスペシャルティCRO
  • CNS (中枢神経系) にフォーカスしたスペシャルティCRO

第8章 ケーススタディI:バーチャルCRO

  • バーチャルCROのイントロダクション
  • Frestedt
  • InSymbiosis
  • Osiris Pharma
  • ProjectPharm
  • The Harte Group
  • VxP Pharma

第9章 ケーススタディII:フルサービスCRO

  • 従来型CROのイントロダクション
  • Covance
  • Medis Research Group
  • Quintiles
  • Triclinium Clinical Trial Project Management

第10章 市場予測

  • 本章の概要
  • 予測手法
  • 世界のスペシャルティCRO市場
  • 地域のスペシャルティCRO市場

第11章 将来の機会

  • 本章の概要
  • 変化するアウトソーシングの状況
  • 医療経済評価 (HEOR) 研究
  • 臨床試験のアダプティブデザイン
  • eクリニカルソリューション
  • リスクに基づくモニタリング (RBM)
  • デジタルCRO (dCRO)

第12章 結論

第13章 インタビュー

第14章 付録1:表データ

第15章 付録2:企業・組織リスト

第16章 付録3:サービスマップ用語

図表

目次
Product Code: RA10055

The biopharmaceutical industry has been witnessing a significant paradigm shift in R&D outsourcing over the last few years. Specialty CROs have emerged as credible players in the market to overcome the shortcomings of full service / traditional CROs. Often, these full service providers offer a wider portfolio of services but fail to align their efforts to meet the requirements of sponsors, primarily the smaller biotech organisations / start-ups. Specialty CROs, on the other hand, specialize in niche areas catering to either specific clinical / preclinical services or providing services in a particular disease area. Oncology, cardiovascular, metabolic disorders and CNS are some of the popular therapeutic areas that have witnessed a rise in the number of specialty CROs. Typically outsourced services include data management, site monitoring and project management but nowadays core services such as pharmacovigilance, target evaluation, formulation development, cell line development, toxicology studies and medical imaging are also being outsourced to these CROs. Specialty CROs are increasingly adopting the strategic CRO model to expand their services and geographical presence in an effort to broaden the scope of serving the global biopharmaceutical industry.

Despite the widening array of services offered by these CROs, they have found it challenging to gain a higher share in the market, which is currently dominated by larger and more well-established players. Considering that a major proportion of revenues for large CROs is generated by big pharma companies, gaps exist when it comes to providing services to smaller pharma / biotech companies. This provides an opportunity to specialty CROs to offer improved, customized and relatively economical services to newer / smaller clients in the sector.

As the demand of novel therapies for various therapeutic areas is expected to rise steadily, we are optimistic about the future of these smaller research firms, which have driven an innovative approach to drug research and development. There are a number of upcoming opportunities that can enrich the service portfolio of speciality CROs gradually strengthening their presence in an otherwise consolidated market.

Synopsis:

The “Specialty CROs Market, 2016-2025” report delivers a comprehensive study on Contract Research Organizations (CROs) that provide a specialized set of research capabilities centred on a particular stage of clinical development or a range of services in a focused therapeutic area. The outsourcing model has proven to be extremely beneficial to drug developers catering to the unmet research, clinical development and even regulatory needs of both established players and start-ups in the market. The concept of specialty CROs continues to evolve as these organizations adopt new strategies to provide their sponsors improved services in terms of both quality and efficiency. Novel business models and strategic partnerships among established and emerging players have opened new avenues to effectively tackle issues such as rising development costs, inefficient protocols and unorganized business processes.

The report assesses key drivers that have governed the evolution of specialty CROs over the past several years, along with an elaborate discussion on the upcoming trends that will likely shape the market in the coming years. In fact, one of the primary objectives of this study is to develop an understanding of the likely future evolution of the market for specialty CROs over the short-term and long-term.

The study presents an in-depth analysis of a diverse set of specialty CROs on some of the key parameters such as geographical location, types of services being offered and focused therapeutic areas. In addition, it captures the potential growth areas that will likely present opportunities for these companies and sustain the pace of growth. It is worth highlighting that despite the fact that established pharmaceutical companies have in-house R&D and clinical development capabilities, the opportunity for specialty CROs is growing. The future evolution of this market will be primarily driven by the relatively fast paced growth of the overall pharma industry and the innovations / developments taking place in R&D. The report provides short-midterm and long-term market forecasts for the period 2016-2020 and 2020-2025, respectively. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The research, analysis and insights presented in this report are backed by a comprehensive survey on capabilities of several specialty CROs. For the purpose of our analysis, we also interviewed important stakeholders in this market to solicit their opinions around the future opportunities and challenges that must be considered for a more inclusive growth.

Example Highlights:

  • 1. Over the last few years, a structural transformation in the primary CRO business model to a more strategic approach has revolutionized R&D outsourcing. Newer players providing specific capabilities in the R&D value chain have witnessed a gradual acceptance.
  • 2. During our research, we have identified over 200 specialty CROs after detailed due diligence of more than 1,000 CROs based on their specific capabilities and the range of services they provide. These specialty CROs collectively cater to the multitude of research services required by drug developers.
  • 3. The US, with ~115 speciality CROs, has emerged as the primary hub of specialty CROs; this is followed by Europe with ~60 CROs. India and China, where CROs offer a relatively higher cost optimized service portfolio, are emerging as new destinations; the level of activity, however, has been fairly limited so far.
  • 4. Though the broader contract research market is highly consolidated and dominated by a handful of bigger CROs, the market within the specialty CRO segment is highly fragmented. This is unlikely to change as biotech companies will continue to prefer outsourcing specific requirements of the clinical trials instead of outsourcing the entire clinical trial programme to an individual CRO.
  • 5. We expect the overall market of specialty CROs to more than double in the coming decade, growing at a CAGR of 8.6%. Specific areas of growth are likely to be driven by novel services and upcoming technologies resulting in cost optimization and improved outputs.
  • 6. Some of the niche opportunity areas / approaches include Health Economics and Outcomes Research (HEOR), adaptive trial designs, and eClinical solutions. Specifically, these areas typify a growing unmet need and represent untapped areas making outsourcing an attractive option.

Research Methodology:

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. The summary offers a high level view on the present scenario of the specialty CRO market and where it is headed in the mid-long term.

Chapter 3 provides a general introduction to CROs. In this chapter, we have discussed, in detail, the evolution of CROs. We have also presented a highly comprehensive CRO services map to highlight the range of services being offered by a large number of CROs operating in different locations worldwide.

Chapter 4 presents specific details on specialty CROs. It provides information about the functioning of specialty CROs along with the specific areas of specialization. We have also discussed the advantages that specialty CROs bring over conventional CROs, focusing on new business models, strategic partnerships and relatively more efficient / integrated business processes.

Chapter 5 provides a holistic global landscape of specialty CROs that we identified in our research. This chapter highlights key aspects of these companies such as their geographical location, year of establishment and R&D capabilities (categorized in terms of specific therapeutic areas and services capabilities offered).

Chapter 6 provides profiles of 18 specialty CROs focused on specialized preclinical / clinical service offering. Each company profile includes an overview of the company, service portfolio, collaborations and associated developments that have recently taken place.

Chapter 7 provides profiles of 12 specialty CROs focused on a particular therapeutic area. Each company profile includes an overview of the company, service portfolio, collaborations and associated developments that have recently taken place.

Chapter 8 is a case study on virtual CROs. We have discussed, in detail, the virtually integrated, cross-functional outsourcing approach implemented by these organizations. In this chapter, we have also focused on various clinical research partnership models that are applied by CROs and their sponsors. The case study also includes profiles of six virtual CROs, some of which are leading players in the market.

Chapter 9 is a case study on full-service CROs. The one-stop-shop approach followed by traditional CROs has been captured in detail in this section. The case study includes profiles of four CROs, some of which are leading players in the market.

Chapter 10 presents a detailed ten year forecast highlighting the future potential for specialty CROs. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market.

Chapter 11 highlights important trends that provide opportunities to specialty CRO to consolidate their presence in this competitive market; amongst others, these include Health Economics and Outcomes Research (HEOR) studies, adaptive trials, eClinical solutions and risk-based monitoring (RBM).

Chapter 12 is a collection of transcript of interviews conducted with key players during the course of this study.

Chapter 13 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our overall opinion on where the market is headed in the mid-long term.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in the report.

Chapter 16 is an appendix, which provides a glossary of the CRO services map.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. History
  • 3.2. Traditional Contract Research Organisations
    • 3.2.1. Services
    • 3.2.2. Current Industry Environment
  • 3.3. Specialty Contract Research Organisations

4. SPECIALTY CROs: AN INTRODUCTION

  • 4.1. Chapter Overview
  • 4.2. Importance of Specialty CROs

5. MARKET OVERVIEW

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Specialty CROs: Global Landscape
    • 5.3.1. Specialty CROs: The Dramatic Rise
    • 5.3.2. Specialty CROs: Distribution by Nature of Specialisation
  • 5.4. Specialty CROs Focused On a Specific Service Capability
    • 5.4.1. Landscape is Well Distributed across Preclinical and Clinical Services
    • 5.4.2. Specialty CROs: Popular Preclinical Services
    • 5.4.3. Specialty CROs: Popular Clinical Services
  • 5.5. Specialty CROs Focused on Specific Therapeutic Area(s)
    • 5.5.1. Oncology is the Most Researched Therapeutic Area
    • 5.5.2. CROs Mostly Located in the US; Europe is a Distant Second

6. SPECIALTY CROs: FOCUSED ON SERVICES

  • 6.1. Chapter Overview
  • 6.2. CROs Focused on Preclinical Service Capabilities
    • 6.2.1. BRI Biopharmaceutical Research
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Focused Clinical Expertise
        • 6.2.1.2.1. API / Clinical Product QC, Dosing Solutions & Materials
        • 6.2.1.2.2. Bioanalytical Assays for Clinical Trials
        • 6.2.1.2.3. Clinical Trial Equipment Rental & PK Sample Collection Kit
        • 6.2.1.2.4. Cynomologus & Rhesus Monkey Hepatocytes & Blood Products
        • 6.2.1.2.5. Drug Candidate Early In Vitro & In Vivo Screening
        • 6.2.1.2.6. In Vitro DMPK & ADME
        • 6.2.1.2.7. In Vivo DMPK & ADME
        • 6.2.1.2.8. Patient Tumor-Derived Xenograft Models at Oncograph™
        • 6.2.1.2.9. Strategic Development of Botanical Drugs
    • 6.2.2. BTS Research
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Focused Clinical Expertise
        • 6.2.2.2.1. Custom Services
        • 6.2.2.2.2. Disease Models
        • 6.2.2.2.3. In Vitro Services
        • 6.2.2.2.4. IND Process
        • 6.2.2.2.5. Medical Devices
        • 6.2.2.2.6. Pharmacology Services
        • 6.2.2.2.7. Toxicology Services
      • 6.2.2.3. Additional Information
        • 6.2.2.3.1. Recent Developments
        • 6.2.2.3.2. Acquisitions
    • 6.2.3. Dorizoe Lifesciences
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Focused Clinical Expertise
        • 6.2.3.2.1. Services and Capabilities
        • 6.2.3.2.2. Customized Services
    • 6.2.4. Fluofarma
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Focused Clinical Expertise
        • 6.2.4.2.1. Assay Development Services
        • 6.2.4.2.1. Cell-based screening services
        • 6.2.4.2.2. In Vitro Drug Profiling Services and Mechanism of Action (MOA) Studies
        • 6.2.4.2.3. Predictive Toxicology Services
        • 6.2.4.2.4. In Vivo Studies
        • 6.2.4.2.5. Biomarker Analysis Services
      • 6.2.4.3. Additional Information
        • 6.2.4.3.1. Collaborations
        • 6.2.4.3.2. Recent Developments
    • 6.2.5. KIYATEC
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Focused Clinical Expertise
        • 6.2.5.2.1. Drug Response Profiling (DRP) Services
      • 6.2.5.3. Additional Information
        • 6.2.5.3.1. Recent Developments
        • 6.2.5.3.2. Funding
    • 6.2.6. Redoxis
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Focused Clinical Expertise
        • 6.2.6.2.1. In Vivo Models
        • 6.2.6.2.2. In Vitro Services
      • 6.2.6.3. Additional Information
        • 6.2.6.3.1. Collaborations
        • 6.2.6.3.2. Recent Developments
        • 6.2.6.3.3. Funding
    • 6.2.7. Spirovation
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Focused Clinical Expertise
        • 6.2.7.2.1. Clinical Assessment
        • 6.2.7.2.2. Functional Screening and Lead Selection
        • 6.2.7.2.3. Target ID and Primary Screening
      • 6.2.7.3. Additional Information
        • 6.2.7.3.1. Facilities
    • 6.2.8. Velesco Pharmaceutical Services
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Focused Clinical Expertise
        • 6.2.8.2.1. Analytical Method Development
        • 6.2.8.2.2. cGMP Manufacturing
        • 6.2.8.2.3. Drug Formulation Development
        • 6.2.8.2.4. Instrumentation
        • 6.2.8.2.5. Pharmaceutical Consulting
  • 6.3. CROs Focused on Clinical Service Capabilities
    • 6.3.1. Almedis
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Focused Clinical Expertise
        • 6.3.1.2.1. Biostatistics
        • 6.3.1.2.2. Clinical Monitoring
        • 6.3.1.2.3. International Clinical Trials
        • 6.3.1.2.4. Local Studies
        • 6.3.1.2.5. Data Management
        • 6.3.1.2.6. Medical Writing
        • 6.3.1.2.7. Training Programs
    • 6.3.2. Applied Healthcare Resource Management
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Focused Clinical Services
      • 6.3.2.3. Additional Information
        • 6.3.2.3.1. Collaborations
    • 6.3.3. CMX Research
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Focused Clinical Expertise
        • 6.3.3.2.1. CRO Services
        • 6.3.3.2.2. Investigator Network
        • 6.3.3.2.3. Investigator-Led Trials (ILTs)
        • 6.3.3.2.4. MDapps™
    • 6.3.4. DSP Clinical Research
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Focused Clinical Expertise
        • 6.3.4.2.1. Data Management
        • 6.3.4.2.2. Monitoring
        • 6.3.4.2.3. Project Management
        • 6.3.4.2.4. Site Management
        • 6.3.4.2.5. Statistics and Medical Writing
        • 6.3.4.2.6. Others
      • 6.3.4.3. Additional Information
        • 6.3.4.3.1. Collaboration
        • 6.3.4.3.2. Recent Developments
    • 6.3.5. DZS Clinical Services
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Focused Clinical Services
        • 6.3.5.2.1. Biostatistics Support and Consulting
        • 6.3.5.2.2. Clinical Data Management
        • 6.3.5.2.3. Clinical Monitoring
        • 6.3.5.2.4. Clinical Project Management
        • 6.3.5.2.5. ClinPlus® eClinical Platform
        • 6.3.5.2.6. Customized FSP Models
        • 6.3.5.2.7. DZS Clinical Sourcing and Staffing
        • 6.3.5.2.8. Medical Coding
        • 6.3.5.2.9. Medical Writing
        • 6.3.5.2.10. Statistical Programming and CDISC Implementation
        • 6.3.5.2.11. SOP Authoring
    • 6.3.6. EthosExcel™
      • 6.3.6.1. Company Overview
      • 6.3.6.2. Focused Clinical Expertise
        • 6.3.6.2.1. Clinical Trial Services
        • 6.3.6.2.2. Clinical Trial Resourcing
        • 6.3.6.2.3. Diversity Consulting
        • 6.3.6.2.4. Investigator and Trial Site Facilitation Services
        • 6.3.6.2.5. Site Management
    • 6.3.7. ICRC-Weyer
      • 6.3.7.1. Company Overview
      • 6.3.7.2. Focused Clinical Expertise
        • 6.3.7.2.1. Biostatistics
        • 6.3.7.2.2. Clinical Data Management
        • 6.3.7.2.3. Medical Review
        • 6.3.7.2.4. Medical Writing
        • 6.3.7.2.5. Safety Writing and Pharmacovigilance
        • 6.3.7.2.6. Scientific Consulting
      • 6.3.7.3. Additional Information
        • 6.3.7.3.1. Expansion of Service Portfolio
    • 6.3.8. Impact Pharmaceutical Services
      • 6.3.8.1. Company Overview
      • 6.3.8.2. Focused Clinical Expertise
        • 6.3.8.2.1. Drug Development Consulting
        • 6.3.8.2.2. Early Phase Clinical Trial Management
        • 6.3.8.2.3. Medical Writing
        • 6.3.8.2.4. Project and Program Management
        • 6.3.8.2.5. Regulatory Affairs
        • 6.3.8.2.6. Regulatory Operations
    • 6.3.9. Research Dynamics Consulting
      • 6.3.9.1. Company Overview
      • 6.3.9.2. Focused Clinical Expertise
        • 6.3.9.2.1. Clinical Monitoring
        • 6.3.9.2.2. Consulting
        • 6.3.9.2.3. GCP Auditing
        • 6.3.9.2.4. Investigator Recruitment
        • 6.3.9.2.5. Project Management
        • 6.3.9.2.6. Site Management
      • 6.3.9.3. Additional Information
        • 6.3.9.3.1. Collaborations
    • 6.3.10. SDS Clinical
      • 6.3.10.1. Company Overview
      • 6.3.10.2. Focused Clinical Expertise
        • 6.3.10.2.1. Clinical Trial Services
        • 6.3.10.2.2. Consulting Services

7. SPECIALTY CROs: FOCUSED ON THERAPEUTIC AREAS

  • 7.1. Chapter Overview
  • 7.2. Specialty CROs Focused on Oncology
    • 7.2.1. Accelovance
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Focused Clinical Expertise
        • 7.2.1.2.1. CRO Services
        • 7.2.1.2.2. Patient Recruitment
        • 7.2.1.2.3. Clinical Call Center
      • 7.2.1.3. Additional Information
        • 7.2.1.3.1. Collaborations
        • 7.2.1.3.2. Site Expansion
    • 7.2.2. Crown Bioscience
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Focused Clinical Expertise
        • 7.2.2.2.1. Biotherapeutics
        • 7.2.2.2.2. Drug Discovery
        • 7.2.2.2.3. Metabolic Diseases
        • 7.2.2.2.4. Oncology
      • 7.2.2.3. Additional Information
        • 7.2.2.3.1. Collaborations
        • 7.2.2.3.2. Service Expansion
        • 7.2.2.3.3. Site Expansion
        • 7.2.2.3.4. Recent Developments
        • 7.2.2.3.5. Funding
    • 7.2.3. MedSource
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Focused Clinical Expertise
        • 7.2.3.2.1. Clinical Data Management and Biostatistics
        • 7.2.3.2.2. Clinical Support
        • 7.2.3.2.3. Clinical Trial Monitoring
        • 7.2.3.2.4. Project Management
        • 7.2.3.2.5. Regulatory Affairs Management
        • 7.2.3.2.6. Study Start-Up
    • 7.2.4. Novella Clinical
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Focused Clinical Expertise
        • 7.2.4.2.1. Clinical Monitoring
        • 7.2.4.2.2. Data Management
        • 7.2.4.2.3. Data Monitoring Committees
        • 7.2.4.2.4. Investigator Strategy & Site Coordination (ISSC)
        • 7.2.4.2.5. Medical Monitoring
        • 7.2.4.2.6. Medical Writing
        • 7.2.4.2.7. Project Management
        • 7.2.4.2.8. Quality Assurance
        • 7.2.4.2.9. Regulatory Affairs
        • 7.2.4.2.10. Safety Management
        • 7.2.4.2.11. Steering Committees & Clinical Advisory Boards
        • 7.2.4.2.12. Training
        • 7.2.4.2.13. Clinical Staffing
        • 7.2.4.2.14. Expertise in Oncology across Various Phases of Clinical Trials
  • 7.3. Specialty CROs Focused on Cardiovascular / Cardiology
    • 7.3.1. Cardialysis
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Focused Clinical Expertise
        • 7.3.1.2.1. Trial Services
        • 7.3.1.2.2. Core Laboratory
        • 7.3.1.2.3. Network of Partners
      • 7.3.1.3. Additional Information
    • 7.3.2. IonsGate Preclinical Services
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Focused Clinical Expertise
        • 7.3.2.2.1. Cell Based Assays
        • 7.3.2.2.2. Isolated Tissue Based Assays
        • 7.3.2.2.3. In Vivo Models
  • 7.4. Specialty CROs Focused on Metabolic Disorders
    • 7.4.1. Betagenex
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Focused Clinical Expertise
        • 7.4.1.2.1. Experimental Services
        • 7.4.1.2.2. Consulting Services
      • 7.4.1.3. Additional Information
    • 7.4.2. Physiogenex
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Focused Clinical Expertise
        • 7.4.2.2.1. Research Services
        • 7.4.2.2.2. Consultancy Services
      • 7.4.2.3. Additional Information
        • 7.4.2.3.1. Collaborations
        • 7.4.2.3.2. Recent Developments
    • 7.4.3. Profil Institute
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Focused Clinical Expertise
        • 7.4.3.2.1. Clinical Development
        • 7.4.3.2.2. Clinical Research
        • 7.4.3.2.3. Data Management and Statistical Services
        • 7.4.3.2.4. Monitoring, Quality & Compliance
        • 7.4.3.2.5. Recruitment Services
        • 7.4.3.2.6. Regulatory Affairs
        • 7.4.3.2.7. Scientific Services
        • 7.4.3.2.8. Experience in Metabolic Disorders
      • 7.4.3.3. Additional Information
        • 7.4.3.3.1. Collaborations
  • 7.5. Specialty CROs Focused on CNS
    • 7.5.1. Biospective
      • 7.5.1.1. Company Overview
      • 7.5.1.2. Focused Clinical Expertise
        • 7.5.1.2.1. Image Processing Technology
        • 7.5.1.2.2. Rodent Models
        • 7.5.1.2.3. Animal Imaging
        • 7.5.1.2.4. Human Imaging and Clinical Trials
        • 7.5.1.2.5. Histology and IHC
    • 7.5.2. RenaSci
      • 7.5.2.1. Company Overview
      • 7.5.2.2. Focused Clinical Expertise
        • 7.5.2.2.1. Experimental Services
        • 7.5.2.2.2. Consultancy Services
      • 7.5.2.3. Additional Information
        • 7.5.2.3.1. Recent Developments
    • 7.5.3. RxGen
      • 7.5.3.1. Company Overview
      • 7.5.3.2. Focused Clinical Expertise
        • 7.5.3.2.1. Efficacy Models
        • 7.5.3.2.2. Custom Model Development
        • 7.5.3.2.3. Pharmacokinetics, Pharmacodynamics and Delivery Optimization Services
        • 7.5.3.2.4. Toxicology and Safety Pharmacology
        • 7.5.3.2.5. Supporting Technologies & Capabilities
      • 7.5.3.3. Additional Information
        • 7.5.3.3.1. Collaboration
        • 7.5.3.3.2. Funding
        • 7.5.3.3.3. Recent Developments

8. CASE STUDY I: VIRTUAL CROs

  • 8.1. Introduction to Virtual CROs
  • 8.2. Frestedt
    • 8.2.1. Company Overview
    • 8.2.2. Service Portfolio
      • 8.2.2.1. Clinical Research
      • 8.2.2.2. Regulatory Affairs
      • 8.2.2.3. Quality Systems
  • 8.3. InSymbiosis
    • 8.3.1. Company Overview
    • 8.3.2. Service Portfolio
      • 8.3.2.1. Drug Discovery
      • 8.3.2.2. Lead Optimization and Efficacy Model
      • 8.3.2.3. Non-Clinical Safety Studies and Bioanalysis
      • 8.3.2.4. Regulatory IND / IMPD filings
      • 8.3.2.5. Document Management
      • 8.3.2.6. Phase I / II/ III Clinical Studies
      • 8.3.2.7. Collaborations
    • 8.3.3. Additional Information
      • 8.3.3.1. Recent Developments
  • 8.4. Osiris Pharma
    • 8.4.1. Company Overview
    • 8.4.2. Service Portfolio
      • 8.4.2.1. Program Management
      • 8.4.2.2. Consultancy
      • 8.4.2.3. Non-clinical Assessment and Management
      • 8.4.2.4. Preclinical Toxicology and Safety Studies
      • 8.4.2.5. Communication and Monitoring
      • 8.4.2.6. Writing and Reviewing of Reports
      • 8.4.2.7. Other Services
  • 8.5. ProjectPharm
    • 8.5.1. Company Overview
    • 8.5.2. Service Portfolio
      • 8.5.2.1. Virtual CRO
      • 8.5.2.2. Project Management Consulting / Organizational Project Management
      • 8.5.2.3. Vendor Selection
      • 8.5.2.4. Financial Audits
      • 8.5.2.5. Training
      • 8.5.2.6. Rescue Studies
      • 8.5.2.7. Study Start-Up
  • 8.6. The Harte Group
    • 8.6.1. Company Overview
    • 8.6.2. Service Portfolio
      • 8.6.2.1. Virtual CRO
      • 8.6.2.2. Consultation
      • 8.6.2.3. Clinical Trial Project Management
      • 8.6.2.4. Integrated Project Delivery and Accountability
  • 8.7. VxP Pharma
    • 8.7.1. Company Overview
    • 8.7.2. Service Portfolio
      • 8.7.2.1. Chemical Development
      • 8.7.2.2. Preclinical
      • 8.7.2.3. Preformulation and Solid State Chemistry
      • 8.7.2.4. Analytical and Bioanalytical
        • 8.7.2.4.1. Analytical Method Development and Validation
        • 8.7.2.4.2. Extractables and Leachables Studies
        • 8.7.2.4.3. Particle Size Determination
        • 8.7.2.4.4. Container-API Compatibility
        • 8.7.2.4.5. Material Characterization
        • 8.7.2.4.6. Forced Degradation and Stability Studies
        • 8.7.2.4.7. Drug Device Compatibility Studies
        • 8.7.2.4.8. Microbial Testing
        • 8.7.2.4.9. Bioanalytical Testing
      • 8.7.2.5. Formulation Development and Clinical Trial materials
      • 8.7.2.6. Parenteral and Lyophilized Clinical Trial Materials
      • 8.7.2.7. Clinical Packaging and Distribution
      • 8.7.2.8. Commercial Services

9. CASE STUDY II: FULL SERVICE CROs

  • 9.1. Introduction to Traditional CROs
  • 9.2. Covance
    • 9.2.1. Company Overview
    • 9.2.2. Service Portfolio
      • 9.2.2.1. Analytical Services
      • 9.2.2.2. Clinical Development
      • 9.2.2.3. Clinical Testing
      • 9.2.2.4. Consulting
      • 9.2.2.5. Health Economics & Market Access
      • 9.2.2.6. Lead Optimization
      • 9.2.2.7. Manufacturing Services
      • 9.2.2.8. Research
      • 9.2.2.9. Safety Assessment
    • 9.2.3. Collaborations
  • 9.3. Medis Research Group
    • 9.3.1. Company Overview
    • 9.3.2 Focused Clinical Expertise
      • 9.3.2.1. Biostatistics
      • 9.3.2.2. Data Management
      • 9.3.2.3. Medical Writing
      • 9.3.2.4. Oncology Expertise
      • 9.3.2.5. Pharmacovigilance
      • 9.3.2.6. Proofreading and Translation
      • 9.3.2.7. RDC System ODM QuaSi®
      • 9.3.2.8. Regulatory Services
      • 9.3.2.9. Scientific Consulting
      • 9.3.2.10. Study Documentation
      • 9.3.2.11. Study Management
      • 9.3.2.12. Study Monitoring
    • 9.3.2.3. Clinical Trial Phase Expertise
    • 9.3.2.4. Additional Information
  • 9.4. Quintiles
    • 9.4.1. Company Overview
    • 9.4.2. Service Portfolio
      • 9.4.2.1. Clinical Trial Execution
      • 9.4.2.2. Consulting
      • 9.4.2.3. Laboratories
      • 9.4.2.4. Real-World and Late Phase
      • 9.4.2.5. Patient and Provider Engagement
      • 9.4.2.6. Product Marketing and Sales
      • 9.4.2.7. Technology Solutions
      • 9.4.2.8. Portfolio and Strategic Planning
    • 9.4.3. Financial Performance
    • 9.4.4. Collaborations
    • 9.4.5. Recent Developments
  • 9.5. Triclinium Clinical Trial Project Management
    • 9.5.1. Company Overview
      • 9.5.1.1. Focused Clinical Expertise
      • 9.5.1.2. Additional Information
        • 9.5.1.2.1. Collaborations

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology
  • 10.3. Global Specialty CROs Market, 2015-2025
  • 10.4. Regional Specialty CROs Market, 2015 - 2025

11. FUTURE OPPORTUNITIES

  • 11.1. Chapter Overview
  • 11.2 The Changing Scenario of Outsourcing
  • 11.3. Health Economics and Outcomes Research (HEOR) Studies
  • 11.4. Adaptive Trial Design
  • 11.5. eClinical Solutions
  • 11.6. Risk Based Monitoring (RBM)
  • 11.7. Digital CRO (dCRO)

12. CONCLUSION

  • 12.1. A Widening Portfolio of Services Governed by Industry Constraints
  • 12.2. Closer Working Collaboration is the Key to Success
  • 12.3. Within Therapeutic Areas, Oncology is the Flagbearer
  • 12.4. Due to Several Niche Offerings, Specialty CRO Market Remains Fragmented
  • 12.5. The Market of Specialty CROs is Likely to Sustain the Growth Momentum
  • 12.6. Untapped Opportunity Areas will Emerge as Key Growth Drivers in the Long-Term
  • 12.7. Concluding Remarks

13. INTERVIEW TRANSCRIPTS

  • 13.1. Chapter Overview
  • 13.2. Raf Magar, President, CRO and Outcomes Research, AHRM
  • 13.3. Jeffrey P. Kiplinger, President, Averica Discovery Services

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

16. APPENDIX 3: SERVICE MAP GLOSSARY

List of Figures:

  • Figure 4.1: Specialty CROs: Benefits
  • Figure 4.2: Specialty CROs: Areas of Specialization
  • Figure 5.1: Specialty CROs: Distribution on the Basis of Year of Foundation
  • Figure 5.2: Specialty CROs: Distribution by Nature of Specialization
  • Figure 5.3: Specialty CRO Services: Stage of Development
  • Figure 5.4: Specialty CROs: Focused Preclinical Services
  • Figure 5.5: Specialty CROs: Focused Clinical Services
  • Figure 5.6: Specialty CROs: Distribution by Focused Therapeutic Areas
  • Figure 5.7: Specialty CROs: Geographical Distribution by Therapeutic Area
  • Figure 6.1: Specialty CROs: Focused Capabilities
  • Figure 6.2: BTS Research: Services for Custom Monoclonal and Polyclonal Antibody
  • Figure 6.3: Dorizoe Lifesciences: Dosage Forms
  • Figure 6.4: Dorizoe Lifesciences: Formulation Development Protocol
  • Figure 6.5: Dorizoe Lifesciences: Customized Services
  • Figure 6.6: Spirovation: Samples and Biomarkers used for Biomarker Evaluation
  • Figure 6.7: Velesco Pharmaceutical Services: Portfolio
  • Figure 6.8: ICRC-Weyer: Biostatistical Services
  • Figure 6.9: ICRC-Weyer: Safety Writing and Pharmacovigilance
  • Figure 6.10: Impact Pharmaceuticals: Medical Writing
  • Figure 7.1: Specialty CROs: Focused Therapeutic Area(S)
  • Figure 7.2: Novella Clinical: EDC and Supporting Systems
  • Figure 7.3: Novella Clinical: Project Management Cycle
  • Figure 7.4: Novella Clinical: Oncological Trial Experience (%)
  • Figure 7.5: Physiogenex: Preclinical Services for First Level Phenotyping and Screening
  • Figure 7.6: Profil Institute: Expertise in Anti-Diabetes Compounds
  • Figure 7.7: Profil Institute: Expertise in Anti-Obesity Compounds and Devices
  • Figure 7.8: Biospective: Rodent Models
  • Figure 7.9: Biospective: Imaging Services For 1.5 and 3T MRI and Brain Pet Studies
  • Figure 7.10: Biospective: Therapeutic Areas for Human Imaging
  • Figure 7.11: Biospective: Services for Quantitative Image Analysis
  • Figure 7.12: Biospective: Stains for Histology and Immunochemistry Studies
  • Figure 8.1: Frestedt: Service Portfolio
  • Figure 8.2: ProjectPharm: Consulting Services
  • Figure 8.3: The Harte Group: Clinical Trial Project Management Services
  • Figure 8.4: VxP Pharma: GLP Radiolabelling Studies
  • Figure 8.5: VxP Pharma: Mammalian and Viral Cell Banks
  • Figure 9.1: Quintiles: Service Revenue, 2010-H1 2015 (USD Million)
  • Figure 10.1: Overall Specialty CROs Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Figure 10.2: Overall Specialty CROs Market, Long Term (2020-2025): Base Scenario (USD Billion)
  • Figure 10.3: Regional Market Forecast, 2015, 2020 And 2025: Base Scenario (USD Billion)
  • Figure 11.1: Specialty CROs: Future Opportunities

List of Tabless:

  • Table 5.1: Specialty CROs: Global Landscape
  • Table 5.2: List of Specialty CROs and their Service Capabilities
  • Table 5.3: Specialty CROs: Classification by Therapeutic Areas
  • Table 6.1: BTS Research: Animal Models for Immune and Inflammatory Diseases
  • Table 6.2: BTS Research: Animal Models for Oncology
  • Table 6.3: BTS Research: Animal Models for CNS
  • Table 7.1: Accelovance China: Services
  • Table 7.2: MedSource: Research Experience in Oncology by Type of Indication
  • Table 7.3: Physiogenex: Animal Models for Diabetes
  • Table 7.4: Physiogenex: Technology Platform for Diabetes
  • Table 7.5: Physiogenex: Animal Models for Dyslipidemia
  • Table 7.6: Physiogenex: Technology Platform for Dyslipidemia
  • Table 7.7: Physiogenex: Animal Models for NAFLD/NASH
  • Table 7.8: Physiogenex: Technology Platform for NAFLD/NASH
  • Table 7.9: Physiogenex: Animal Models for Obesity
  • Table 7.10: Physiogenex: Technology Platform for Obesity
  • Table 7.11: Physiogenex: Animal Models for Nutraceuticals
  • Table 7.12: Physiogenex: Technology Platforms for Nutraceuticals
  • Table 8.1: VxP Pharma: Systems Suitable for E/L testing
  • Table 14.1: Specialty CROs: Distribution by Year of Foundation
  • Table 14.2: Specialty CROs: Distribution by Nature of Specialization
  • Table 14.3: Specialty CRO Services: Stage of Development
  • Table 14.4: Specialty CROs: Focused Preclinical Services
  • Table 14.5: Specialty CROs: Focused Clinical Services
  • Table 14.6: Specialty CROs: Distribution by Focused Therapeutic Areas
  • Table 14.7: Specialty CROs: Geographical Distribution by Therapeutic Area
  • Table 14.8: Novella Clinical: Oncological Trial Experience (%)
  • Table 14.9: Quintiles: Service Revenue, 2010-H1 2015 (USD Million)
  • Table 14.10: Overall Specialty CROs Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Table 14.11: Overall Specialty CROs Market, Long Term (2020-2025): Base Scenario (USD Billion)
  • Table 14.12: Regional Market Forecast, 2015, 2020 and 2025: Base Scenario (USD Billion)
  • Table 14.13: Overall Specialty CROs Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
  • Table 14.14: Overall Specialty CROs Market, Long Term (2020-2025): Conservative Scenario (USD Billion)
  • Table 14.15: Regional Market Forecast, 2015, 2020 and 2025: Conservative Scenario (USD Billion)
  • Table 14.16: Overall Specialty CROs Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
  • Table 14.17: Overall Specialty CROs Market, Long Term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 14.18: Regional Market Forecast, 2015, 2020 and 2025: Optimistic Scenario (USD Billion)
  • Table 14.19: Specialty CROs Market: Comparative Market Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)

List of Companies

The following companies and organisations have been mentioned in this report.

  • 1. Abiogenesis Clinpharm
  • 2. Accell Clinical Research
  • 3. Accelovance
  • 4. Aclires
  • 5. Acquipharma
  • 6. Afraxis
  • 7. Agence Africaine de Recherche en Santé Humaine
  • 8. Agility Clinical
  • 9. Agilux Laboratories
  • 10. AHRM
  • 11. AIT Bioscience
  • 12. Aklima Clinical Research
  • 13. Alera Labs
  • 14. Alimentix
  • 15. Alliance Pharma
  • 16. Allied Clinical Management
  • 17. Allostem Therapeutics
  • 18. Almedis
  • 19. Alpha CRO
  • 20. Alpha Stats
  • 21. Altair Clinical
  • 22. Altiora CRO
  • 23. Altree Healthcare
  • 24. Alturas Analytics
  • 25. Amarex Clinical Research
  • 26. Amclin Life Sciences
  • 27. American Physical Therapy Association
  • 28. AMSlab
  • 29. Anolinx
  • 30. APEX Research
  • 31. Appletree CI Group
  • 32. Applied Clinical Research & Consulting Group
  • 33. Applied Healthcare Resource Management
  • 34. Apricus Biosciences
  • 35. ARAC
  • 36. Arete Clinical Research
  • 37. Argonaut Private Equity
  • 38. Aris Global
  • 39. Arkios BioDevelopment International
  • 40. Association for Assessment and Accreditation of Laboratory Animal Care International
  • 41. Association of Clinical Research Organizations
  • 42. Association of Clinical Research Professionals
  • 43. Aston University
  • 44. Athena Discovery
  • 45. Atlantic Bone Screen
  • 46. Atuka
  • 47. Audubon PM Associates
  • 48. Auxilis Pharma
  • 49. Averica Discovery Services
  • 50. Avitacor
  • 51. Axonal
  • 52. B. McLaughlin Associates
  • 53. Banook Group
  • 54. Betagenex
  • 55. Biaffin GmbH & Co
  • 56. Biogen
  • 57. BioLink Life Sciences
  • 58. BioPharma Services
  • 59. Bio-Quant
  • 60. BioSkin CRO
  • 61. Biospective
  • 62. Biotrofix Preclinical CRO
  • 63. Bordeaux University
  • 64. Boston Biomedical Associates
  • 65. Boston Regulatory Consulting
  • 66. BRI Biopharmaceutical Research
  • 67. BTS Research
  • 68. Burrill & Company
  • 69. Cambridge Biomedical
  • 70. Canadian Council of Animal Care
  • 71. CAP Trials
  • 72. Cardialysis
  • 73. Cardiomedex
  • 74. CDIB Capital Investment
  • 75. Center Point Clinical Services
  • 76. Cerafor
  • 77. Charles River Laboratories
  • 78. Chimera Biotec
  • 79. Cica Biomedical
  • 80. CIDP Biotech India
  • 81. Cirion Clinical Trial Services
  • 82. CirQuest Labs
  • 83. ClinAudits
  • 84. ClinBAY
  • 85. ClinDatrix
  • 86. Clinical Research Consulting
  • 87. Clinilabs
  • 88. CliniRx Tangent Research
  • 89. ClinIST Research Education and Consulting
  • 90. Clinitrial CRO
  • 91. ClinROC
  • 92. Clinvest
  • 93. CMX Research
  • 94. CNBE
  • 95. Concentrics Research
  • 96. Courante Oncology
  • 97. Covance
  • 98. CPR Pharma Services
  • 99. CRC Pharma
  • 100. CRDE
  • 101. Creagen Biosciences
  • 102. CRO Solutions
  • 103. Cros NT
  • 104. Crown Bioscience
  • 105. Crownbio Taicang Biologics Division
  • 106. Crystal Pharmatech
  • 107. Cu Tech
  • 108. CuriRX
  • 109. Cyprotex
  • 110. Cytespace Africa
  • 111. DATATRAK International
  • 112. David H Murdock Research Institute
  • 113. DaVita Clinical Research
  • 114. DiaVacs
  • 115. Dinox
  • 116. Diverse Lynx
  • 117. DOCRO
  • 118. Dorizoe Lifesciences
  • 119. DSP Clinical Research
  • 120. DZS Clinical Services
  • 121. EarlyPhase Sciences
  • 122. Eastern Clinical Trials
  • 123. Eckert & Ziegler Vitalea Science
  • 124. Ecron Acunova
  • 125. Elucid Bioimaging
  • 126. EmpiriStat
  • 127. EMRI CRO Greece
  • 128. Encore Health Services
  • 129. Ephoran
  • 130. ERA Clinical
  • 131. Erudita Biotechnical
  • 132. EthosExcel™
  • 133. Euprotec
  • 134. European Cardiovascular Research Institute
  • 135. European Food Safety Authority
  • 136. European Medical Writers Association
  • 137. Federation of European Laboratory Animal Science Association
  • 138. Fermish
  • 139. First Clinical Network
  • 140. Flow Contract Site Laboratory
  • 141. FlowMetric
  • 142. FluoFarma
  • 143. Foster Delivery Services
  • 144. Frenova Renal Research
  • 145. Frestedt
  • 146. Frontline Monitors
  • 147. Gadea Grupo Farmacéutico
  • 148. Gateway Pharmacology Laboratories
  • 149. Getz Pharma Research
  • 150. Global Specimen Solutions
  • 151. Greenville Health System
  • 152. Gubra
  • 153. Harlan Laboratories
  • 154. Health Canada
  • 155. Health Sciences Authority
  • 156. HealthLinx
  • 157. Hengrui Medicine
  • 158. HJ-Clinical Trial Consultancy
  • 159. Horizon Discovery
  • 160. Hospital Italiano of Buenos Aires
  • 161. Huntingdon Life Sciences
  • 162. IBT Management Corporation
  • 163. ICE Bioscience
  • 164. ICRC-Weyer
  • 165. IMMR
  • 166. Impact Pharmaceutical Services
  • 167. Inamed
  • 168. Inclinix
  • 169. Innova CRO
  • 170. Innovaderm Research
  • 171. InrexTest
  • 172. Institute for Translational Oncology Research
  • 173. InSymbiosis
  • 174. Integral Biosystems
  • 175. International Drug Development Institute
  • 176. Ionic Transport Assays
  • 177. IonsGate Preclinical Services
  • 178. IPSEN
  • 179. Iris Pharma
  • 180. Jasco Pharmaceuticals
  • 181. JV AgroBiotech
  • 182. KalVista Pharmaceuticals
  • 183. Karolinska Development
  • 184. KCAS
  • 185. KCRI
  • 186. Kiyatec
  • 187. Klinikos Consulting
  • 188. KPS
  • 189. LabCorp Clinical Trials
  • 190. Lekoko PMC
  • 191. LEMI
  • 192. Life Science Alley
  • 193. Lilly Asia Ventures
  • 194. Lotus Clinical Research
  • 195. LU Bioscience
  • 196. Marsico Lung Institute
  • 197. MCT
  • 198. Medelis
  • 199. Medepha
  • 200. Medicines and Healthcare Products Regulatory Agency
  • 201. Medicon Valley Inhalation Consortium
  • 202. Medis Research Group
  • 203. MedSource
  • 204. Merck Serono
  • 205. Mercodia
  • 206. Michigan Life Science and Innovation Center
  • 207. MicroConstants
  • 208. Midwest Melanoma Partnership
  • 209. miRagen Therapeutics
  • 210. MMS Holdings
  • 211. Modoc Research Services
  • 212. Molecular Imaging
  • 213. Molecular Response
  • 214. Montrium
  • 215. NAMSA Medvance
  • 216. Nanjing Biotech Innovation Corporation
  • 217. National Cancer Institute
  • 218. National Institutes of Health
  • 219. National Resource Center for Mutant Mice
  • 220. Neuregenix
  • 221. NeuroDiscovery
  • 222. Neuron Experts
  • 223. NeuroSciences
  • 224. New England Research Institute
  • 225. New York State Center of Excellence in Bioinformatics and Life Sciences
  • 226. NexMed
  • 227. Next Generation Clinical Research
  • 228. Novella Clinical
  • 229. NSF International
  • 230. Numira
  • 231. Nutrition Coordinating Center
  • 232. Octagon Research Solutions
  • 233. Oncotherapeutics
  • 234. Oneiric International
  • 235. OnkoDataMed
  • 236. OnPoint CRO
  • 237. OrbiMed Advisors
  • 238. Orbis Data Solutions
  • 239. Organon
  • 240. Osiris Pharma
  • 241. Oss lab
  • 242. P3 Research
  • 243. Pacific Nutritional Research
  • 244. PAIRimmune
  • 245. Panacea Pharmaceuticals
  • 246. Pfizer
  • 247. PharmaLegacy
  • 248. PharmaPhase Management
  • 249. PharSafer Associates
  • 250. Phenotype Expertise
  • 251. PhylogenX
  • 252. Physiogenex
  • 253. PhysioStim
  • 254. Pioneer Clinical Data
  • 255. Pneumolabs
  • 256. Preclinical Oncology Services
  • 257. Profil Institut für Stoffwechselforschungh
  • 258. ProjectPharm
  • 259. Prologue Research
  • 260. Prometrika
  • 261. ProNoxis
  • 262. ProQinase
  • 263. ProTrials
  • 264. Provonix
  • 265. QED Clinical Services
  • 266. QuailCRO
  • 267. Quanticate
  • 268. Quest Diagnostics
  • 269. Quintiles
  • 270. Redoxis
  • 271. Renaissance Associates
  • 272. RenaSci
  • 273. Research Dynamics Consulting Group
  • 274. Research Point Clinical
  • 275. Roche
  • 276. RxGen
  • 277. SAGE Labs
  • 278. Sahana Clinical Research
  • 279. SBH Sciences
  • 280. SCIderm
  • 281. Scimega
  • 282. SDS Clinical
  • 283. Servier
  • 284. Shanghai Institute of Materia Medica
  • 285. Shin Nippon Biomedical Laboratories
  • 286. Simbec Research
  • 287. Skills Alliance
  • 288. SMS-oncology
  • 289. Spirovation
  • 290. Sristek
  • 291. Stat Pro
  • 292. Surpass
  • 293. SwedenBIO
  • 294. Symbiance
  • 295. Symmetry Biosciences
  • 296. Synchrogenix
  • 297. SynCon International
  • 298. Synergo BioPharma
  • 299. Synergy
  • 300. Synsight
  • 301. Sysmex Corporation
  • 302. TAB Clinical Trials
  • 303. Tandem Labs
  • 304. TCNSC
  • 305. Team WomenMN
  • 306. Techtrials International
  • 307. TFS Trial Form Support
  • 308. The CID Group
  • 309. The Harte Group
  • 310. The Medical Affairs Company
  • 311. The Total Approach
  • 312. Therapeutic Goods Administration
  • 313. Therinova
  • 314. Tillväxtverket
  • 315. Topstone Research
  • 316. Toxikon Corporation
  • 317. Translational Research Institute
  • 318. Trial-IN
  • 319. Triclinium Clinical Research
  • 320. Tufts University
  • 321. Universidad de Valladolid
  • 322. University College Dublin
  • 323. University of Erlangen
  • 324. Vanton Research Laboratory
  • 325. Velesco Pharmaceutical Services
  • 326. Vinnova
  • 327. VirtualScopics
  • 328. Visionar Preclinical
  • 329. Voxcan
  • 330. VR Analytical
  • 331. VxP Pharma
  • 332. Wildcat Pharmaceutical Development Center
  • 333. William Harvey Research
  • 334. World Health Organization
  • 335. Xenometrics
  • 336. Xerox Corp
  • 337. Xstrahl
  • 338. YAKUMED
  • 339. 2KMM
Back to Top